Cover Image

BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial

BRCA1 is an important protein in the repair of DNA double strand breaks (DSBs), which are induced by alkylating chemotherapy. A BRCA1-like DNA copy number signature derived from tumors with a BRCA1 mutation is indicative for impaired BRCA1 function and associated with good outcome after high dose (H...

Full description

Saved in:
Bibliographic Details
Main Authors: Schouten, Philip (Author) , Gluz, Oleg (Author) , Harbeck, Nadia (Author) , Mohrmann, Svjetlana (Author) , Diallo‐Danebrock, Raihana (Author) , Pelz, Enrico (Author) , Kruizinga, Janneke (Author) , Velds, Arno (Author) , Nieuwland, Marja (Author) , Kerkhoven, Ron M. (Author) , Liedtke, Cornelia (Author) , Frick, Markus (Author) , Kates, Ronald (Author) , Linn, Sabine C. (Author) , Nitz, Ulrike (Author) , Marmé, Frederik (Author)
Format: Article (Journal)
Language:English
Published: 3 Mar 2016
In: International journal of cancer
Year: 2016, Volume: 139, Issue: 4, Pages: 882-889
ISSN:1097-0215
DOI:10.1002/ijc.30078
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1002/ijc.30078
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.30078
Get full text
Author Notes:Philip C. Schouten, Oleg Gluz, Nadia Harbeck, Svjetlana Mohrmann, Raihana Diallo‐Danebrock, Enrico Pelz, Janneke Kruizinga, Arno Velds, Marja Nieuwland, Ron M. Kerkhoven, Cornelia Liedtke, Markus Frick, Ronald Kates, Sabine C. Linn, Ulrike Nitz and Frederik Marme
Description
Summary:BRCA1 is an important protein in the repair of DNA double strand breaks (DSBs), which are induced by alkylating chemotherapy. A BRCA1-like DNA copy number signature derived from tumors with a BRCA1 mutation is indicative for impaired BRCA1 function and associated with good outcome after high dose (HD) and tandem HD DSB inducing chemotherapy. We investigated whether BRCA1-like status was a predictive biomarker in the WSG AM 01 trial. WSG AM 01 randomized high-risk breast cancer patients to induction (2× epirubicin-cyclophosphamide) followed by tandem HD chemotherapy with epirubicin, cyclophosphamide and thiotepa versus dose dense chemotherapy (4× epirubicin-cyclophospamide followed by 3× cyclophosphamide-methotrexate-5-fluorouracil).
Item Description:Gesehen am 22.05.2020
Physical Description:Online Resource
ISSN:1097-0215
DOI:10.1002/ijc.30078

Similar Items